company background image
STEN

Stenocare CPSE:STENO Stock Report

Last Price

kr.11.32

Market Cap

kr.129.3m

7D

-3.1%

1Y

-19.1%

Updated

22 May, 2022

Data

Company Financials
STENO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

STENO Stock Overview

Stenocare A/S cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products in the Danish and European markets.

Stenocare Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Stenocare
Historical stock prices
Current Share Pricekr.11.32
52 Week Highkr.19.78
52 Week Lowkr.6.85
Beta-0.38
1 Month Change-7.97%
3 Month Change3.85%
1 Year Change-19.14%
3 Year Changen/a
5 Year Changen/a
Change since IPO-69.97%

Recent News & Updates

Mar 29
Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Nov 29
We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

STENODK PharmaceuticalsDK Market
7D-3.1%1.7%3.5%
1Y-19.1%18.0%2.3%

Return vs Industry: STENO underperformed the Danish Pharmaceuticals industry which returned 18% over the past year.

Return vs Market: STENO underperformed the Danish Market which returned 2.3% over the past year.

Price Volatility

Is STENO's price volatile compared to industry and market?
STENO volatility
STENO Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement6.5%
10% most volatile stocks in DK Market10.9%
10% least volatile stocks in DK Market3.9%

Stable Share Price: STENO is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: STENO's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aThomas Schnegelsberghttps://stenocare.dk

Stenocare A/S cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products in the Danish and European markets. It offers medical cannabis oil products. Stenocare A/S was founded in 2017 and is headquartered in Allerød, Denmark.

Stenocare Fundamentals Summary

How do Stenocare's earnings and revenue compare to its market cap?
STENO fundamental statistics
Market Capkr.129.29m
Earnings (TTM)-kr.13.60m
Revenue (TTM)kr.2.37m

54.6x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STENO income statement (TTM)
Revenuekr.2.37m
Cost of Revenuekr.8.82m
Gross Profit-kr.6.46m
Other Expenseskr.7.15m
Earnings-kr.13.60m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 15, 2022

Earnings per share (EPS)-1.19
Gross Margin-272.85%
Net Profit Margin-574.87%
Debt/Equity Ratio15.3%

How did STENO perform over the long term?

See historical performance and comparison

Valuation

Is Stenocare undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.54x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STENO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STENO's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: STENO is unprofitable, so we can't compare its PE Ratio to the European Pharmaceuticals industry average.

PE vs Market: STENO is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STENO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STENO is overvalued based on its PB Ratio (3.5x) compared to the XE Pharmaceuticals industry average (2.5x).


Future Growth

How is Stenocare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stenocare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Stenocare performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-67.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: STENO is currently unprofitable.

Growing Profit Margin: STENO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STENO is unprofitable, and losses have increased over the past 5 years at a rate of 67.8% per year.

Accelerating Growth: Unable to compare STENO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STENO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.9%).


Return on Equity

High ROE: STENO has a negative Return on Equity (-37.28%), as it is currently unprofitable.


Financial Health

How is Stenocare's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: STENO's short term assets (DKK16.4M) exceed its short term liabilities (DKK1.6M).

Long Term Liabilities: STENO's short term assets (DKK16.4M) exceed its long term liabilities (DKK6.7M).


Debt to Equity History and Analysis

Debt Level: STENO has more cash than its total debt.

Reducing Debt: Insufficient data to determine if STENO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STENO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: STENO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36.3% each year


Dividend

What is Stenocare current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate STENO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STENO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STENO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STENO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STENO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average board tenure


CEO

Thomas Schnegelsberg (56 yo)

no data

Tenure

Mr. Thomas Skovlund Schnegelsberg serves as Chief Executive Officer and Co-Founder of Stenocare A/S. Mr. Schnegelsberg serves as Deputy Chairman of Bagsværd Kost- & Gymnasium Skole. Mr. Schnegelsberg serve...


Board Members

Experienced Board: STENO's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Stenocare A/S's employee growth, exchange listings and data sources


Key Information

  • Name: Stenocare A/S
  • Ticker: STENO
  • Exchange: CPSE
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr.129.289m
  • Shares outstanding: 11.42m
  • Website: https://stenocare.dk

Location

  • Stenocare A/S
  • Frederiksborgvej 54
  • Allerød
  • Capital Region of Denmark
  • 3450
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.